
|Videos|May 14, 2019
Dr. Oratz on PARP Inhibitors to Treat Patients With Breast Cancer
Author(s)Ruth Oratz, MD
Cancer Network spoke with Ruth Oratz, MD, a medical oncologist at NYU Langone Perlmutter Cancer Center in New York City, about the use of PARP inhibitors for breast cancer.
Advertisement
Cancer Network spoke with Ruth Oratz, MD, a medical oncologist and breast cancer specialist at NYU Langone Perlmutter Cancer Center in New York City, about the use of poly (ADP-ribose) polymerase inhibitors for patients diagnosed with breast cancer.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma
3
2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?
4
Real World Outcomes of CAR T-Cell Therapy in Multiple Myeloma Including Older and Comorbid Patients
5



































